Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 14/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.70 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037194 | 0.87 | MAPK13 (0.63) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7037212 | 0.87 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7035001 | 0.86 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7039009 | 0.83 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7037530 | 0.83 | MAPK13 (0.72) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL2201099 | 0.82 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6656897 | 0.82 | MAPK14 (0.82) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7039968 | 0.81 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7198813 | 0.81 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7038906 | 0.80 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | claimed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | claimed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | claimed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | claimed |
| EP-1289958-A2 | BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) | Leo Pharma A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| US-6432962-B2 | Benzophenones as inhibitors of IL-1β and TNF-α | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-08-13 | — | — | US | disclosed |
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| WO-2001090074-A2 | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | LEO PHARMA A/S (DK) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016347-A1 | Benzophenones as inhibitors of IL-1beta and TNF-alpha | IL1B, IL1A, NFKBIA | MAPK14 625/4885MAPK13 1908/4885MAPK12 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.